26.08.2010
- Sanofi-Aventis shareholders L'oreal and Total worry that the French drugmaker will pay too much for U.S. biotech company Genzyme and are not convinced it is the best fit, bankers...
26.08.2010
- Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar...
19.08.2010
- A senior Johnson & Johnson pharmaceuticals executive will now also oversee the company's consumer healthcare unit, following quality control lapses that led to massive recalls of...
13.08.2010
- Looking back, moving forward - The fine chemical industry has gone through a few difficult periods in the last decennium. More recently, however, the market has improved quite a...
13.08.2010
- Hard to Copy - Market data shows that sales of biotech products are worth billions of dollars worldwide - just the sort of prospect that normally brings generic manufacturers...
09.08.2010
- Paris-based drugmaker Sanofi-Aventis may need weeks of haggling to get a deal on buying U.S. biotech firm Genzyme as the two appear wide apart over price. Neither party has...
04.08.2010
- Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...
04.08.2010
- Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group. Two...
03.08.2010
- Sanofi-Aventis chief executive Chris Viehbacher should aim to land U.S. biotech group Genzyme for around$19 billion to keep his investors on side, according to institutional...
02.08.2010
- Chances are, every big pharmaceutical company is running the numbers and weighing the pros and cons of acquiring Genzyme. French drugmaker Sanofi-Aventis is poised to make a bid...
